Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant

Brian A Mc Ardle1, Ross A Davies1, Li Chen1

  • 1From the Division of Cardiology, Department of Medicine (B.A.M.A., R.A.D., G.R.S., T.D.R., G.D., Y.Y., H.H., L.M.M., E.S., R.H., R.S.B., B.J.W.C.), National Cardiac PET Center (B.A.M.A., R.A.D., T.D.R., R.H., A.G., R.S.B., R.A.d., B.J.W.C.), and Division of Cardiology, Department of Medicine, Cardiovascular Research Methods Center (L.C.), University of Ottawa Heart Institute. Ottawa, Canada.

Insights

Rubidium-82 positron emission tomography can identify cardiac allograft vasculopathy after heart transplant. Abnormalities in myocardial flow reserve and blood flow predict adverse events in these patients.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Transplantation

Background:

  • Cardiac allograft vasculopathy (CAV) significantly impacts prognosis after heart transplantation.
  • Accurate detection and risk stratification of CAV remain challenging.
  • Rubidium-82 positron emission tomography (Rb-82 PET) offers quantitative myocardial blood flow (MBF) assessment, potentially aiding risk stratification.

Purpose of the Study:

  • To evaluate the utility of dipyridamole Rb-82 PET for risk stratification in heart transplant recipients.
  • To determine if quantitative MBF parameters predict adverse clinical outcomes in this population.

Main Methods:

  • Prospective enrollment of 140 heart transplant patients undergoing dipyridamole Rb-82 PET.
  • Quantification of absolute MBF at rest and stress, and calculation of myocardial flow reserve (MFR).
  • Follow-up for all-cause death, acute coronary syndrome, and heart failure hospitalization.

Main Results:

  • 14 adverse events occurred during a median follow-up of 18.2 months.
  • Lower MFR and reduced mean stress MBF were significant predictors of adverse outcomes.
  • Relative perfusion defects also correlated with adverse events.

Conclusions:

  • Abnormalities detected by Rb-82 PET, including reduced MFR and stress MBF, predict adverse events in heart transplant patients.
  • These findings suggest Rb-82 PET's potential role in managing CAV.
  • Larger studies are needed to validate these results.
Abstract

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
844
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.2K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
713